Investment Rating - The report maintains a "Buy" rating with a target price of HKD 9.81 [4] Core Insights - The company has successfully renewed multiple products in the 2024 National Medical Insurance Directory, including Tevizo and HER2 monoclonal antibody, and has added a new indication for Tevizo in pediatric ITP [1][2] - The company is expected to see stable pricing for renewed products due to ongoing support from the medical insurance fund for innovative drugs, which will contribute to steady growth [1][2] - The company’s revenue is projected to grow by 12.8% in 2024 and 12.2% in 2025, with a corresponding net profit growth of 13.6% in 2025 [4] Summary by Sections - **Product Renewals and New Additions**: Tevizo and HER2 monoclonal antibody have been successfully renewed, with Tevizo gaining a new indication for pediatric ITP. The newly approved drug, sodium naftifine oral disintegrating tablet, has also entered the medical insurance directory [1][2] - **Pipeline Development**: The company is advancing its pipeline with several innovative products entering NDA or Phase III clinical trials, expected to be approved between 2025E and 2027E, providing new growth momentum [1][3] - **Sales and Market Expansion**: The company has established a robust sales capability across various channels, including blood, oncology, nephrology, and rheumatology, and is continuously enriching its innovative pipeline [3] - **Valuation Metrics**: The current market capitalization corresponds to 6.6 times the estimated PE for 2025, indicating an attractive valuation. The expected dividend payout ratio is 30%, with a projected dividend yield of 4.5% for 2025 [1][4]

Investment Rating - The report assigns a positive outlook on New World Development, indicating a new development cycle under the leadership of the new management team [2]. Core Insights - The appointment of Huang Shaomei as the CEO is expected to enhance the company's operations in both Hong Kong and mainland China, leveraging her extensive experience in real estate [2]. - The company has a land reserve of 3.72 million square meters, with 58% located in the Greater Bay Area and Yangtze River Delta, which supports its long-term growth strategy [2]. - The company has successfully divested non-core assets, with sales reaching HKD 8 billion in the fiscal year 2024 and projected to reach HKD 13 billion in fiscal year 2025 [2]. - Financing activities have been robust, with over HKD 50 billion in loans arranged and debt repayments completed in 2024, including the issuance of USD 400 million bonds [2]. - Recent policy adjustments in the real estate sector are expected to stabilize the mainland property market, particularly in the key regions of Guangzhou and Shanghai [2]. Summary by Sections Management Changes - Huang Shaomei has been appointed as the CEO, bringing over 20 years of real estate experience, which is anticipated to strengthen the company's strategic direction [2]. Financial Performance - The company reported a market capitalization of HKD 16.132 billion and a share price of HKD 6.41, with a 52-week high of HKD 11.98 and a low of HKD 6.20 [2]. Asset Management - The company is focusing on core assets in prime locations and has ongoing urban renewal projects, which differentiate its competitive position [2]. Financing Strategy - The company has completed significant financing arrangements, including long-term, low-interest loans totaling RMB 5.8 billion, with an average cost of 3.1% [2].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 26.82, indicating a potential upside of 28.0% from the current price of HKD 20.95 [5][6]. Core Insights - The company's revenue for the first three quarters of 2024 reached CNY 442.42 billion, a year-on-year decrease of 0.78%. The overall gross margin declined by 0.68 percentage points to 7.55%, and the net profit attributable to shareholders was CNY 5.279 billion, down 13.41% year-on-year [2]. - In Q3, the company experienced a revenue growth of 1.88% year-on-year, primarily due to a low base effect from the previous year, with a quarter-on-quarter growth of only 0.16%. The net profit for Q3 was CNY 1.575 billion, reflecting a year-on-year decrease of 20.94% [2]. Summary by Sections Pharmaceutical Distribution - The pharmaceutical distribution business showed a stable growth of 0.47% in the first half of the year. The company focused on key regions such as Jiangsu, Zhejiang, Shanghai, Central China, North China, and Guangxi, where revenue share has been increasing, leading to a growing market share. The direct sales to medical institutions slightly decreased, but retail direct sales increased due to the company's channel advantages [3]. Medical Device Distribution and Retail - The medical device distribution business faced significant pressure, with a revenue decline of 7.08% in the first half of the year. Although the distribution of medical consumables remained relatively stable, revenues from high-margin products like medical equipment and IVD test reagents decreased, impacting the overall gross margin [4]. - The retail business also suffered from a reduction in individual medical accounts and intensified competition, leading to a 6.43% year-on-year decline in retail revenue to CNY 16.6 billion. The company took measures such as closing loss-making stores, resulting in a narrowed loss for its retail subsidiary in Q3 [4]. Financial Metrics - The company has a total share capital of 3.121 billion shares and a market capitalization of HKD 64.75 billion. The stock has a 52-week high of HKD 23.65 and a low of HKD 16.02, with a net asset value per share of HKD 27.46 [5].

Investment Rating - The report initiates coverage on Aikang Medical (1789.HK) with a "Buy" rating and a target price of HKD 6.8, indicating a potential upside of 27% from the current price of HKD 5.4 [4][5]. Core Views - Aikang Medical, as a leading domestic orthopedic joint company, continues to demonstrate strong bidding performance in the ongoing national procurement of joint products, despite short-term industry disruptions due to anti-corruption measures. The company is expected to see improved visibility in revenue growth in 2025 as these risks clear [1][2]. - The long-term growth potential is supported by Aikang's focus on technological research and development, being the first in China to apply metal 3D printing in orthopedic implants. The company aims to leverage 3D printing, ICOS, and surgical robots to create a digital orthopedic platform, expanding its presence in the mid-to-high-end market [2][3]. Financial Forecasts and Valuation - Revenue is projected to grow from RMB 1,052 million in 2022 to RMB 1,990 million by 2026, with a compound annual growth rate (CAGR) of 22% from 2023 to 2026. The expected revenue growth rates for the years 2024, 2025, and 2026 are 19.3%, 24.5%, and 22.5%, respectively [3][14][97]. - The net profit is forecasted to increase from RMB 205 million in 2022 to RMB 399 million by 2026, with significant growth anticipated in 2025 [3][14][97]. - The report assigns a target price based on a price-to-earnings (PE) ratio of 22x for 2025E, aligning with the company's historical average [2][97]. Industry Overview - The orthopedic industry is currently facing short-term pressures due to anti-corruption measures, but it is expected to benefit in the long term from a large patient base, increasing surgical penetration rates, and domestic product substitution [1][16]. - The national procurement of orthopedic consumables has largely been implemented, with joint products being the first to undergo this process. The average price drop in the recent procurement round was around 6%, indicating a moderate impact on pricing [24][57]. - The domestic orthopedic implant market's localization rate is approximately 50%, with significant room for improvement as domestic brands gain market share through national procurement initiatives [27][29]. Product Development and Innovation - Aikang Medical has a comprehensive product layout in the joint category, having launched various generations of knee and hip joint replacement products since 2004. The company has also expanded its product line through strategic acquisitions, enhancing its technological capabilities and market reach [52][53]. - The introduction of the ICOS platform allows for customized orthopedic solutions, which is expected to drive sales in the mid-to-high-end market segment [62][64]. International Expansion - Aikang Medical employs a dual-brand strategy with Aikang and JRI in overseas markets, focusing on cost-effectiveness and stable product quality. The company aims to increase its overseas revenue contribution from 19% in 1H24 to over 30% in the medium to long term [93][94].

Investment Rating - The report maintains a "Buy" rating for Baidu Group-SW (09888) with a target price of HKD 137 [1] Core Views - Baidu's Q3 2024 total revenue was RMB 33.6 billion, down 3% YoY, with Non-GAAP net profit of RMB 5.9 billion, down 19% YoY [1] - Baidu Core revenue was RMB 26.5 billion, with online marketing revenue at RMB 18.8 billion, down 4% YoY due to macroeconomic challenges [1] - Non-online marketing revenue grew 12% YoY to RMB 7.7 billion, driven by AI Cloud, which contributed RMB 4.9 billion, up 11% YoY [1] - AI revenue accounted for 11% of total AI Cloud revenue, with iQIYI revenue at RMB 7.2 billion, down 10% YoY [1] - The company's strong technical advantages in AI infrastructure are expected to drive further growth in AI Cloud revenue [1] AI Cloud & ERNIE - Baidu expanded its ERNIE series with two enhanced lightweight models, Speed Pro and Lite Pro [1] - ERNIE processed approximately 1.5 billion API calls daily in November, up from 600 million in August, indicating strong market adoption [1] - ERNIE Agent's daily conversations reached 15 million, with monthly active users at 704 million, up 6% YoY [1] - AI-generated content in search results increased from 18% to 20%, with AI features covering nearly 70% of Baidu App's monthly active users [1] Profitability - Non-GAAP operating profit for Q3 2024 was RMB 7 billion, with an operating margin of 26% [1] - The company expects continued improvement in operating margins as user behavior on Baidu Search improves [1] Autonomous Driving - Baidu's autonomous driving service, Apollo Go, provided approximately 988,000 rides in Q3 2024, up 20% YoY [1] - As of October 28, 2024, Apollo Go has completed over 8 million rides, with the sixth-generation autonomous vehicle, Apollo RT6, priced competitively below USD 30,000 [1] Investment Recommendation - The report adjusts revenue forecasts for FY2024-2026 to RMB 1338/1476/1641 billion, with Non-GAAP operating profit adjusted to RMB 274/308/342 billion [1] - The target price of HKD 137 is based on a SOTP valuation, assigning 8x P/E for advertising, 3x P/S for cloud business, and 14x P/E for iQIYI's non-advertising revenue [1] - The "Buy" rating is maintained due to Baidu's ongoing AI transformation and investments in AI Cloud and autonomous driving [1]

Investment Rating - The report maintains a "Buy" rating for Meituan with a target price raised to HK$240.00 from HK$193.00, indicating a potential upside of 39% from the current price of HK$172.20 [2][3][10]. Core Insights - Meituan's 3Q24 performance showed stable and sustainable profit growth, with revenue and operating profit growth in the instant delivery segment outpacing order volume growth [6][10]. - The report highlights a healthy growth forecast for the dine-in and travel segments, with expected revenue and operating profit growth of 25% year-on-year in 4Q24 [7][10]. - The report emphasizes the improvement in profitability prospects for core local businesses, including food delivery and dine-in services, leading to a projected 23% year-on-year growth in operating profit for 2025 [10][18]. Financial Summary - Revenue for 2024 is projected at RMB 336,900 million, with an expected year-on-year growth of 22% [11][17]. - Adjusted EPS for 2024 is forecasted to be RMB 7.47, reflecting a 15% increase from previous estimates [9][17]. - The adjusted net income for 2024 is expected to reach RMB 47,348 million, with a net profit margin of 14.1% [11][17]. Segment Performance - The instant delivery segment reported a 14.5% year-on-year increase in order volume, with management projecting that flash purchase orders could eventually capture 10% of the Chinese e-commerce market [8][10]. - The dine-in and travel segment saw a 50% increase in order volume in 3Q24, with revenue growth of 25% year-on-year [10][11]. - New business losses narrowed to RMB 10 billion in 3Q24, down from RMB 13 billion in 2Q24, indicating a trend towards improved profitability [10][11]. Valuation - The report employs a sum-of-the-parts (SOTP) valuation approach, estimating the food delivery business at USD 78 billion and the dine-in and travel business at USD 49 billion, both based on a 15x P/E ratio for 2025 [18][20][22]. - The community e-commerce and local retail business is valued at USD 63 billion, using a 0.8x P/GMV multiple for 2025 [20][22].

Investment Rating - The report maintains a "Buy" rating for Xiaomi Group with a target price of HK$34.00, indicating a potential upside of 20% from the current price of HK$28.30 [2][3][8]. Core Insights - The report emphasizes the structural growth opportunities for Xiaomi in the Southeast Asian market, driven by smartphone replacement cycles and increasing IoT product penetration [6][17][22]. - Despite challenges in overseas markets, Xiaomi's revenue contribution from international markets has increased to 45% in 2023, up from 36% in 2020, indicating a shift towards emerging markets as key growth drivers [17][19]. - The report highlights the potential for Xiaomi to capture a larger market share in Southeast Asia, with expectations of an increase from 15% in Q3 2024 to approximately 18% by 2026 [46][48]. Financial Summary - Revenue projections for Xiaomi are as follows: RMB 356,281 million for 2024E, RMB 423,470 million for 2025E, and RMB 465,323 million for 2026E [11]. - Earnings per share (EPS) estimates are projected at RMB 0.99 for 2024E, RMB 1.08 for 2025E, and RMB 1.24 for 2026E, reflecting a growth trajectory [11]. - The report notes a significant increase in the average price of smartphones in Southeast Asia, with potential market value growth of 13% driven by rising prices [35][36]. Market Opportunities - The Southeast Asian smartphone market is expected to see a structural growth opportunity, with a projected increase in smartphone shipments to 17 million units by 2026, driven by a shortening replacement cycle [29][31]. - The report identifies that the average smartphone price in Southeast Asia is currently lower than in China, suggesting room for price increases as 5G penetration grows [35][38]. - Xiaomi's IoT product offerings are expected to drive significant traffic and sales growth in the region, with a focus on enhancing product accessibility and expanding SKU variety [62][67]. Competitive Landscape - Xiaomi ranks among the top three smartphone vendors in Southeast Asia, alongside Samsung and Oppo, with a competitive edge in both high-end and low-end market segments [46][48]. - The report indicates that Xiaomi's market share has fluctuated due to challenges faced in overseas markets, but there is optimism for recovery and growth in market share through strategic initiatives [46][48]. - The report also highlights the importance of enhancing retail experiences and expanding distribution networks to capture market opportunities effectively [59][63].

Investment Rating - The report maintains a **Buy** rating for New World Development (17 HK) with a target price of HKD 11.44, representing a potential upside of **74.5%** from the current price of HKD 6.56 [1][3] Core Views - New management is expected to improve operational efficiency, particularly in the mainland China business, with the appointment of Ms. Wong Siu Mui as CEO [1] - The company has completed the sale of NEW WORLD SPORTS DEVELOPMENT LIMITED (NWSPL) for HKD 416.7 million, which is expected to help recover investment costs and reduce financial burdens [2] - Sales progress is strong, with HKD 3.7 billion in attributable sales completed in Hong Kong (62% of FY2025 guidance) and RMB 4.8 billion in contracted sales in mainland China, with expectations to reach RMB 7 billion by the end of 2024 (64% of full-year guidance) [2] - The stock is currently trading at around **0.1x P/B**, which is believed to reflect most negative factors, with potential re-rating catalysts including improved operational efficiency, strong FY2025 sales progress, reduced capex, and potential interest rate cuts [3] Financial Summary - Revenue is expected to decline by **34.4% YoY** in FY2024 to HKD 35,782 million but rebound by **20.2% YoY** in FY2025 to HKD 42,999 million [4] - Core profit is projected to decrease by **47.5% YoY** in FY2024 to HKD 1,377 million but recover by **19.8% YoY** in FY2025 to HKD 1,648 million [4] - The company's P/E ratio is expected to improve from **12.0x** in FY2024 to **10.0x** in FY2025 [4] - Dividend yield is forecasted to increase from **3.0%** in FY2024 to **4.0%** in FY2025 [4] Operational Highlights - The company has established separate operating committees for Hong Kong and mainland China businesses to enhance operational efficiency [1] - The launch of Guangzhou Kaixuan New World is expected to contribute to mainland China sales, with contracted sales projected to reach RMB 7 billion by the end of 2024 [2] Industry Context - The report covers other Hong Kong and mainland China real estate companies, including Sun Hung Kai Properties (16 HK), Link REIT (823 HK), and Henderson Land (12 HK), with varying ratings and target prices [8]

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 56.20, indicating a potential upside of 21.1% from the current price of HKD 46.40 [1][11]. Core Insights - The successful inclusion of the drug "耐赋康" (EVER001) in the national medical insurance directory is expected to drive significant sales growth, with projected sales reaching RMB 12.2 billion and RMB 18.3 billion for 2025 and 2026, respectively [2]. - The report highlights the promising clinical results of EVER001, a reversible BTK inhibitor, which has shown high rates of clinical remission in patients with membranous nephropathy, a condition with increasing prevalence [1][2]. - The market potential for EVER001 is substantial, as it is the only drug approved for the IgA nephropathy indication in the national medical insurance directory, providing a significant first-mover advantage [2]. Financial Projections - Revenue projections for the company have been revised upwards, with expected revenues of RMB 744 million for 2024, RMB 1.765 billion for 2025, and RMB 2.951 billion for 2026, reflecting increases of 17.4% and 15.3% for the latter two years compared to previous forecasts [3][13]. - The net profit forecast for 2026 has been adjusted to RMB 409 million, a significant improvement from previous estimates [3][13]. - The gross profit margin is expected to improve to 79.0% by 2026, indicating enhanced operational efficiency [3][13]. Market Context - The report notes that the incidence of membranous nephropathy is rising, with approximately 2 million patients in China and significant numbers in the US, Europe, and Japan, highlighting the growing market opportunity for the company's products [1][2]. - The company is positioned in the biotechnology sector, which is experiencing robust growth, particularly in the development of innovative therapies for unmet medical needs [11].

Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Insights - The company achieved a total sales of 229.1 billion yuan from January to November 2024, with a year-on-year decline of 19.9%, but the decline rate has narrowed compared to previous months, indicating a recovery trend in sales [1]. - The company is actively increasing its core land reserves, with a total land reserve area of 56.99 million square meters, of which over 70% is located in first- and second-tier cities [2]. - The asset management business is steadily growing, with a total asset management scale reaching 449.1 billion yuan, primarily driven by shopping centers [3]. Summary by Sections Sales Performance - The company ranked third in the "Top 100 Real Estate Companies" by total sales, improving its position from the previous year [1]. - The sales area reached 9.95 million square meters, with a year-on-year decline of 17.5% [1]. Land Acquisition - In the first half of 2024, the company added 2.02 million square meters of land reserves, with 87% of the investment in first- and second-tier cities [2]. - In October and November 2024, the company acquired 850,000 square meters of land in key cities, with a total land cost of 41.4 billion yuan [2]. Asset Management - The company operates 82 shopping centers with a total area of 10.45 million square meters, achieving a high occupancy rate of 97.3% [3]. - The operational revenue from the asset management business reached 38.7 billion yuan, reflecting a year-on-year growth of 13.1% [3]. Financial Forecast - The core EPS for 2024-2026 is projected to be 3.64, 3.72, and 3.88 yuan, respectively, with corresponding PE ratios of 6.0, 5.9, and 5.6 times [4].